Get Your Own Businessabc AI Visibility ID
Boost AI visibility, credibility, and discoverability
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Genocea Biosciences, Inc. was founded in 2013 as a biopharmaceutical company focusing on the development of new drugs that utilize the body's natural anti-inflammatory and anti-cancer defense mechanisms. The company has developed the PENTARAY Target Discovery Platform, which can access the pool of epitopes recognized by the human immune system to select multiple therapeutic targets for its candidate vaccines and for inhibiting T-cell disfunction associated with infectious diseases.
Our mission is to create innovative immunotherapeutics to fight cancer and infectious disease by leveraging powerful insights into the biology of the human immune system.
Our vision is to make a difference for patients by providing treatments that save and improve lives.
